Specific IgG4 antibodies to cow's milk proteins in pediatric patients with eosinophilic esophagitis - 04/07/18
Abstract |
Background |
Allergen-specific IgG4 (sIgG4) antibodies are often associated with tolerance, but sIgG4 antibodies to causally relevant foods have been reported recently in adults with eosinophilic esophagitis (EoE). Prevalence and levels of food sIgG4 are not well established in the general pediatric population.
Objective |
We sought to investigate serum food sIgG4 with component diagnostics in children with EoE and children from an unselected birth cohort and to explore the effects of sex, age, and milk consumption on sIgG4 levels.
Methods |
Sera from 71 pediatric patients with EoE and 210 early adolescent children from an unselected birth cohort (Project Viva) were assayed for sIgG4 and specific IgE (sIgE) to major cow's milk (CM) proteins (α-lactalbumin, β-lactoglobulin, and caseins) and to wheat, soy, egg, and peanut proteins.
Results |
In the EoE cohort high-titer sIgG4 (≥10 μg/mL) to CM proteins was more common than in control sera and achieved odds ratios for EoE ranging from 5.5 to 8.4. sIgE levels to CM proteins were mostly 4 IU/mL or less in patients with EoE, such that sIgG4/sIgE ratios were often 10,000 or greater. When adjusted for age and milk consumption, high-titer sIgG4 to CM proteins was strongly associated with EoE, with an odds ratio of greater than 20 to all 3 CM proteins in boys.
Conclusions |
sIgG4 to CM proteins are common and high titer in children with EoE. Although it is not clear that this response is pathogenic, sIgG4 levels imply that these antibodies are an important feature of the local immune response that gives rise to EoE.
Le texte complet de cet article est disponible en PDF.Graphical abstract |
Key words : Eosinophilic esophagitis, children, IgG4 assays, cow's milk proteins, molecular allergens
Abbreviations used : CM, CSR, EoE, α-gal, hpf, ISAC, OR, sIgE, sIgG4
Plan
Supported by funding from National Institutes of Health grants R01-AI-20565 (to T.A.E.P-M.) and K23-AI-059317 (to E.A.E.). Project Viva is supported by grants R01-AI-102960 and R01-HD-034568. |
|
Disclosure of potential conflict of interest: E. C. McGowan received grant KAI123596A for this work from National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases. J. Lidholm is employed by Thermo Fisher Scientific. S. L. Rifas-Shiman's and E. Oken's institutions received a grant from the NIH for this work. D. R. Gold's institution received a grant and support for travel from NIH for this work. T. A. E. Platts-Mills received a grant from the NIH and support from Phadia/Thermo Fisher during the conduct of the study. E. A. Erwin received royalties from UpToDate. The rest of the authors declare that they have no relevant conflicts of interest. |
Vol 142 - N° 1
P. 139 - juillet 2018 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?